A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)
SpringWorks Therapeutics, Inc.
Masonic Cancer Center, University of Minnesota
Novartis
National Institutes of Health Clinical Center (CC)
AstraZeneca
Healx Limited
University of Alabama at Birmingham
University of Alabama at Birmingham
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Massachusetts General Hospital
AstraZeneca
National Institutes of Health Clinical Center (CC)
NFlection Therapeutics, Inc.
Johns Hopkins University
University of Alabama at Birmingham
AstraZeneca
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
AstraZeneca
Pasithea Therapeutics Corp.
Massachusetts General Hospital
Massachusetts General Hospital
Massachusetts General Hospital
Cedars-Sinai Medical Center
Children's Hospital Medical Center, Cincinnati
The Hospital for Sick Children
Vanderbilt University
Children's National Research Institute
Vanderbilt University
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Medical College of Wisconsin
University of Alabama at Birmingham
Yale University
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Murdoch Childrens Research Institute
Massachusetts General Hospital
Massachusetts General Hospital
West China Hospital
National Cancer Institute (NCI)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Pfizer
Children's Hospital Medical Center, Cincinnati